MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-03-2022
Codiak BioSciences Revenue 2011-2026 | CDAK
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Codiak BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.9 M | 2.92 M | 388 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | 388 K | 8.75 M |
Quarterly Revenue Codiak BioSciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 522 K | - | 12.7 M | - | 1.16 M | 890 K | 13.2 M | - | 954 K | 187 K | 134 K | - | 151 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.2 M | 134 K | 3.32 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Esperion Therapeutics
ESPR
|
403 M | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
2.32 B | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Fortress Biotech
FBIO
|
63.3 M | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Galapagos NV
GLPG
|
1.11 B | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
10.1 B | $ 27.7 | 0.59 % | $ 17.1 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 8.37 | 1.2 % | $ 6.83 B |  Spain |
 |
BioNTech SE
BNTX
|
482 M | $ 94.84 | -0.69 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
29.3 K | $ 2.44 | 24.11 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
203 M | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Kamada Ltd.
KMDA
|
180 M | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
INmune Bio
INMB
|
50 K | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
Kymera Therapeutics
KYMR
|
39.2 M | $ 85.73 | 3.65 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
1.07 M | $ 12.98 | -3.49 % | $ 1.72 B |  Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
158 M | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.55 | 1.43 % | $ 5.84 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M |  Canada |
 |
Mirum Pharmaceuticals
MIRM
|
521 M | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
349 M | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 23.48 | 0.26 % | $ 2.99 B | USA |
 |
Nanobiotix S.A.
NBTX
|
32.6 M | $ 41.5 | 19.36 % | $ 286 B | France |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |